Phage display has become an invaluable tool for the discovery of novel therapeutic agents, including nanobodies.
NGS offers an approach for identifying and extracting variable domain heavy-chain (VHH) regions from camelid B-cells.
In the fight against infectious diseases, scientists are continually seeking to outsmart pathogens. One such strategy involves the use of nanobodies.
An emerging therapeutic strategy to tackle cancer is nanobodies – small, single-domain antibody fragments derived from heavy-chain-only antibodies.
Nanobodies, also known as single-domain antibodies or VHHs, are small, highly stable, and specific antibody fragments.